Transgenomic Debt to Equity Ratio 2010-2023 | PRPO
Current and historical debt to equity ratio values for Transgenomic (PRPO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Transgenomic debt/equity for the three months ending September 30, 2023 was 0.01.
| Transgenomic Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-09-30 |
$0.01B |
$0.01B |
0.47 |
| 2023-06-30 |
$0.01B |
$0.01B |
0.38 |
| 2023-03-31 |
$0.01B |
$0.01B |
0.37 |
| 2022-12-31 |
$0.01B |
$0.02B |
0.31 |
| 2022-09-30 |
$0.01B |
$0.02B |
0.29 |
| 2022-06-30 |
$0.01B |
$0.02B |
0.26 |
| 2022-03-31 |
$0.01B |
$0.02B |
0.26 |
| 2021-12-31 |
$0.01B |
$0.03B |
0.24 |
| 2021-09-30 |
$0.01B |
$0.03B |
0.22 |
| 2021-06-30 |
$0.01B |
$0.03B |
0.23 |
| 2021-03-31 |
$0.01B |
$0.02B |
0.40 |
| 2020-12-31 |
$0.01B |
$0.01B |
0.46 |
| 2020-09-30 |
$0.01B |
$0.01B |
0.50 |
| 2020-06-30 |
$0.01B |
$0.01B |
0.51 |
| 2020-03-31 |
$0.01B |
$0.01B |
0.68 |
| 2019-12-31 |
$0.01B |
$0.01B |
0.48 |
| 2019-09-30 |
$0.01B |
$0.02B |
0.47 |
| 2019-06-30 |
$0.01B |
$0.01B |
0.56 |
| 2019-03-31 |
$0.01B |
$0.01B |
1.20 |
| 2018-12-31 |
$0.02B |
$0.01B |
2.53 |
| 2018-09-30 |
$0.02B |
$0.01B |
1.69 |
| 2018-06-30 |
$0.01B |
$0.01B |
1.12 |
| 2018-03-31 |
$0.01B |
$0.01B |
0.95 |
| 2017-12-31 |
$0.01B |
$0.01B |
1.09 |
| 2017-09-30 |
$0.02B |
$0.02B |
0.71 |
| 2017-06-30 |
$0.02B |
$0.02B |
0.87 |
| 2017-03-31 |
$0.02B |
$-0.02B |
-1.06 |
| 2016-12-31 |
$0.01B |
$-0.01B |
-1.13 |
| 2016-09-30 |
$0.02B |
$-0.02B |
-1.12 |
| 2016-06-30 |
$0.02B |
$-0.02B |
-1.19 |
| 2016-03-31 |
$0.02B |
$-0.02B |
-1.23 |
| 2015-12-31 |
$0.02B |
$-0.01B |
-1.38 |
| 2015-09-30 |
$0.02B |
$0.01B |
2.64 |
| 2015-06-30 |
$0.02B |
$0.01B |
1.88 |
| 2015-03-31 |
$0.02B |
$0.01B |
2.43 |
| 2014-12-31 |
$0.02B |
$0.01B |
3.58 |
| 2014-09-30 |
$0.02B |
$0.01B |
2.02 |
| 2014-06-30 |
$0.02B |
$0.01B |
2.00 |
| 2014-03-31 |
$0.02B |
$0.01B |
1.15 |
| 2013-12-31 |
$0.02B |
$0.01B |
1.65 |
| 2013-09-30 |
$0.02B |
$0.02B |
1.16 |
| 2013-06-30 |
$0.02B |
$0.02B |
0.87 |
| 2013-03-31 |
$0.02B |
$0.02B |
0.72 |
| 2012-12-31 |
$0.02B |
$0.02B |
0.91 |
| 2012-09-30 |
$0.02B |
$0.02B |
0.90 |
| 2012-06-30 |
$0.02B |
$0.03B |
0.76 |
| 2012-03-31 |
$0.02B |
$0.03B |
0.82 |
| 2011-12-31 |
$0.02B |
$0.01B |
2.04 |
| 2011-09-30 |
$0.03B |
$-0.00B |
-20.92 |
| 2011-06-30 |
$0.03B |
$0.00B |
275.58 |
| 2011-03-31 |
$0.03B |
$0.01B |
4.62 |
| 2010-12-31 |
$0.02B |
$0.01B |
2.77 |
| 2010-09-30 |
$0.01B |
$0.01B |
0.50 |
| 2010-06-30 |
$0.00B |
$0.01B |
0.45 |
| 2010-03-31 |
$0.01B |
$0.01B |
0.45 |
| 2009-12-31 |
$0.00B |
$0.01B |
0.37 |
| 2009-09-30 |
$0.00B |
$0.01B |
0.34 |
| 2009-06-30 |
$0.00B |
$0.01B |
0.35 |
| 2009-03-31 |
$0.01B |
$0.01B |
0.37 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Information Systems |
$0.010B |
$0.015B |
|
Precipio Inc. has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. Precipio Inc., formerly known as Transgenomic Inc., is based in Omaha, United States of America.
|
